111614
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
信迪利单抗联合新辅助放化疗治疗高危局部晚期直肠癌的安全性和有效性：一项回顾性研究
Authors Tian M, Zhao M, Jiang L, Liu J, Shen G, Zhang Z, Zhu C, Zhang S, Sun X, Shi Y, Di X
Received 24 August 2025
Accepted for publication 19 November 2025
Published 27 November 2025 Volume 2025:17 Pages 2931—2938
DOI https://doi.org/10.2147/CMAR.S562917
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Professor Harikrishna Nakshatri
Meng Tian,1,2,* Minghui Zhao,2,* Linhong Jiang,2,* Jia Liu,2,* Gefenqiang Shen,2 Zhaoyue Zhang,2,3 Caiqiang Zhu,1 Sheng Zhang,2 Xinchen Sun,2 Yujing Shi,1 Xiaoke Di1,2
1Department of Oncology, Jurong Hospital Affiliated to Jiangsu University, Zhenjiang, People’s Republic of China; 2Department of Radiation Oncology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, People’s Republic of China; 3Department of Oncology, The Affiliated Suqian First People’s Hospital of Nanjing Medical University, Suqian, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Yujing Shi, Email Jing1208519910@163.com Xiaoke Di, Email dixiaoke@njmu.edu.cn
Background: Neoadjuvant chemoradiotherapy (nCRT) followed by total mesorectal excision (TME) is the standard treatment regimen for locally advanced rectal cancer (LARC). However, pathologic complete response (pCR) rates remain suboptimal, and distant metastasis remains a significant cause of treatment failure. While immune checkpoint inhibitors (ICIs) has demonstrated promising efficacy and safety in microsatellite instability-high (MSI-H) rectal cancer patients, less than 5% of rectal cancers exhibit MSI-H characteristics. The majority are microsatellite stable (MSS) types, which are generally unresponsive to immunotherapy alone. Recent studies have indicated that the addition of radiotherapy can convert immune checkpoint-insensitive “cold” tumors into more responsive “hot” tumors. Therefore, combining immunotherapy with nCRT may enhance the pCR rate and improve prognosis in LARC patients.
Objective: The study aimed to evaluate the safety and efficacy of serplulimab in combination with conventional nCRT for treating LARC, particularly in patients with high-risk factors.
Methods: A retrospective analysis was conducted using data from patients with LARC treated at the First Affiliated Hospital with Nanjing Medical University between November 2023 and July 2024. All enrolled patients received conventional radiotherapy combined with CapeOX or capecitabine monotherapy, along with serplulimab, followed by TME 8– 12 weeks post-nCRT. The primary endpoint was the pCR rate, while secondary endpoints included the incidence of adverse events.
Results: A total of 29 patients were enrolled, with a median age of 60 years. About 79.3% patients had tumors located within 10 cm from the anal margin. Pre-treatment stages were uniformly categorized as IIIB or IIIC, with 51.7% classified as cT4 and 86.2% as cN2. Additionally, 65.5% exhibited tumor invasion of the mesorectal fascia. All 29 patients underwent R0 resection. Postoperative pathology revealed that 31.0% (9/29) patients achieved tumor regression grade (TRG) 0, 31.0% (9/29) patients achieved TRG 1. The most common adverse events included lymphocytopenia, fatigue, neutropenia, and anal pain. Grade 3 toxicity was observed in 48.3% of patients, with no grade 4 or 5 adverse reactions noted.
Conclusion: The combination of serplulimab with nCRT demonstrated safety and efficacy in patients with high-risk pMMR LARC. However, further verification through longer follow-up periods and large-scale prospective studies is warranted.
Keywords: locally advanced rectal cancer, neoadjuvant chemoradiotherapy, serplulimab, neoadjuvant immunotherapy, pathological complete response
1Department of Oncology, Jurong Hospital Affiliated to Jiangsu University, Zhenjiang, People’s Republic of China; 2Department of Radiation Oncology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, People’s Republic of China; 3Department of Oncology, The Affiliated Suqian First People’s Hospital of Nanjing Medical University, Suqian, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Yujing Shi, Email Jing1208519910@163.com Xiaoke Di, Email dixiaoke@njmu.edu.cn
Background: Neoadjuvant chemoradiotherapy (nCRT) followed by total mesorectal excision (TME) is the standard treatment regimen for locally advanced rectal cancer (LARC). However, pathologic complete response (pCR) rates remain suboptimal, and distant metastasis remains a significant cause of treatment failure. While immune checkpoint inhibitors (ICIs) has demonstrated promising efficacy and safety in microsatellite instability-high (MSI-H) rectal cancer patients, less than 5% of rectal cancers exhibit MSI-H characteristics. The majority are microsatellite stable (MSS) types, which are generally unresponsive to immunotherapy alone. Recent studies have indicated that the addition of radiotherapy can convert immune checkpoint-insensitive “cold” tumors into more responsive “hot” tumors. Therefore, combining immunotherapy with nCRT may enhance the pCR rate and improve prognosis in LARC patients.
Objective: The study aimed to evaluate the safety and efficacy of serplulimab in combination with conventional nCRT for treating LARC, particularly in patients with high-risk factors.
Methods: A retrospective analysis was conducted using data from patients with LARC treated at the First Affiliated Hospital with Nanjing Medical University between November 2023 and July 2024. All enrolled patients received conventional radiotherapy combined with CapeOX or capecitabine monotherapy, along with serplulimab, followed by TME 8– 12 weeks post-nCRT. The primary endpoint was the pCR rate, while secondary endpoints included the incidence of adverse events.
Results: A total of 29 patients were enrolled, with a median age of 60 years. About 79.3% patients had tumors located within 10 cm from the anal margin. Pre-treatment stages were uniformly categorized as IIIB or IIIC, with 51.7% classified as cT4 and 86.2% as cN2. Additionally, 65.5% exhibited tumor invasion of the mesorectal fascia. All 29 patients underwent R0 resection. Postoperative pathology revealed that 31.0% (9/29) patients achieved tumor regression grade (TRG) 0, 31.0% (9/29) patients achieved TRG 1. The most common adverse events included lymphocytopenia, fatigue, neutropenia, and anal pain. Grade 3 toxicity was observed in 48.3% of patients, with no grade 4 or 5 adverse reactions noted.
Conclusion: The combination of serplulimab with nCRT demonstrated safety and efficacy in patients with high-risk pMMR LARC. However, further verification through longer follow-up periods and large-scale prospective studies is warranted.
Keywords: locally advanced rectal cancer, neoadjuvant chemoradiotherapy, serplulimab, neoadjuvant immunotherapy, pathological complete response